|
1
|
Ling C, Chen G, Chen G, Zhang Z, Cao B,
Han K, Yin J, Chu A, Zhao Y and Mao X: A Deuterated analog of
dasatinib disrupts cell cycle progression and displays
anti-non-small cell lung cancer activity in vitro and in vivo. Int
J Cancer. 131:2411–2419. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pasquini G and Giaccone G: C-MET
inhibitors for advanced non-small cell lung cancer. Expert Opin
Investig Drugs. 27:363–375. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mazzarella L, Guida A and Curigliano G:
Cetuximab for treating non-small cell lung cancer. Expert Opin Biol
Ther. 18:483–493. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun YW, Xu J, Zhou J and Liu WJ: Targeted
drugs for systemic therapy of lung cancer with brain metastases.
Oncotarget. 9:5459–5472. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thomas SM and Brugge JS: Cellular
functions regulated by Src family kinases. Annu Rev Cell Dev Biol.
13:513–609. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koppikar P, Choi SH, Egloff AM, Cai Q,
Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM
and Grandis JR: Combined inhibition of c-Src and epidermal growth
factor receptor abrogates growth and invasion of head and neck
squamous cell carcinoma. Clin Cancer Res. 14:4284–4291. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nan Y, Du J, Ma L, Jiang H, Jin F and Yang
S: Early Candidate biomarkers of non-small cell lung cancer are
screened and identified in premalignant lung lesions. Technol
Cancer Res Treat. 16:66–74. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Kalyankrishna S, Wislez M,
Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM and
Kurie JM: SRC-family kinases are activated in non-small cell lung
cancer and promote the survival of epidermal growth factor
receptor-dependent cell lines. Am J Pathol. 170:366–376. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnson FM, Saigal B, Talpaz M and Donato
NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses
invasion and induces cell cycle arrest and apoptosis of head and
neck squamous cell carcinoma and non-small cell lung cancer cells.
Clin Cancer Res. 11:6924–6932. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ceppi P, Papotti M, Monica V, Lo Iacono M,
Saviozzi S, Pautasso M, Novello S, Mussino S, Bracco E, Volante M
and Scagliotti GV: Effects of Src kinase inhibition induced by
dasatinib in non-small cell lung cancer cell lines treated with
cisplatin. Mol Cancer Ther. 8:3066–3074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kiefer PE, Wegmann B, Bacher M, Erbil C,
Heidtmann H and Havemann K: Different pattern of expression of
cellular oncogenes in human non-small-cell lung cancer cell lines.
J Cancer Res Clin Oncol. 116:29–37. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu X, Han K, Zhu J, Mao H, Lin X, Zhang Z,
Cao B, Zeng Y and Mao X: An inhibitor of cholesterol absorption
displays anti-myeloma activity by targeting the JAK2-STAT3
signaling pathway. Oncotarget. 7:75539–75550. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han K, Xu X, Chen G, Zeng Y, Zhu J, Du X,
Zhang Z, Cao B, Liu Z and Mao X: Identification of a promising PI3K
inhibitor for the treatment of multiple myeloma through the
structural optimization. J Hematol Oncol. 7:92014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu X, Wang J, Han K, Li S, Xu F and Yang
Y: Antimalarial drug mefloquine inhibits nuclear factor kappa B
signaling and induces apoptosis in colorectal cancer cells. Cancer
Sci. 109:1220–1229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu X, Han K, Tang X, Zeng Y, Lin X, Zhao
Y, Zhang Z, Cao B, Wu D and Mao X: The ring finger protein RNF6
induces leukemia cell proliferation as a direct target of
pre-B-cell leukemia homeobox 1. J Biol Chem. 291:9617–9628. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen G, Xu X, Tong J, Han K, Zhang Z, Tang
J, Li S, Yang C, Li J, Cao B, et al: Ubiquitination of the
transcription factor c-MAF is mediated by multiple lysine residues.
Int J Biochem Cell Biol. 57:157–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu X, Zhang J, Han K, Zhang Z, Chen G,
Zhang J, Mao X and Cao B: Natural pesticide dihydrorotenone arrests
human plasma cancer cells at the G0/G1 phase of the cell cycle. J
Biochem Mol Toxicol. 28:232–238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kohlmaier A, Fassnacht C, Jin Y, Reuter H,
Begum J, Dutta D and Edgar BA: Src kinase function controls
progenitor cell pools during regeneration and tumor onset in the
Drosophila intestine. Oncogene. 34:2371–2384. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ,
Sams SB, Lund GS, Sharma V, Haugen BR and Schweppe RE: Targeted
inhibition of Src kinase with dasatinib blocks thyroid cancer
growth and metastasis. Clin Cancer Res. 18:3580–3591. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alinari L, Prince CJ, Edwards RB, Towns
WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, et
al: Dual targeting of the Cyclin/Rb/E2F and mitochondrial pathways
in mantle cell lymphoma with the translation inhibitor silvestrol.
Clin Cancer Res. 18:4600–4611. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
O'Connor PM, Jackman J, Jondle D, Bhatia
K, Magrath I and Kohn KW: Role of the p53 tumor suppressor gene in
cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell
lines. Cancer Res. 53:4776–4780. 1993.PubMed/NCBI
|
|
22
|
Matsuoka S, Edwards MC, Bai C, Parker S,
Zhang P, Baldini A, Harper JW and Elledge SJ: p57KIP2, a
structurally distinct member of the p21CIP1 Cdk inhibitor family,
is a candidate tumor suppressor gene. Genes Dev. 9:650–662. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sarin N, Engel F, Kalayda GV, Mannewitz M,
Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde
U and Frötschl R: Cisplatin resistance in non-small cell lung
cancer cells is associated with an abrogation of cisplatin-induced
G2/M cell cycle arrest. PLoS One. 12:e01810812017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin X, Qiu F and Zou Z: TRIM25 is
associated with cisplatin resistance in non-small-cell lung
carcinoma A549 cell line via downregulation of 14-3-3sigma. Biochem
Biophys Res Commun. 493:568–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feng X, Liu H, Zhang Z, Gu Y, Qiu H and He
Z: Annexin A2 contributes to cisplatin resistance by activation of
JNK-p53 pathway in non-small cell lung cancer cells. J Exp Clin
Cancer Res. 36:1232017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ochi N, Takigawa N, Harada D, Yasugi M,
Ichihara E, Hotta K, Tabata M, Tanimoto M and Kiura K: Src mediates
ERK reactivation in gefitinib resistance in non-small cell lung
cancer. Exp Cell Res. 322:168–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Remon J, Vilariño N and Reguart N: Immune
checkpoint inhibitors in non-small cell lung cancer (NSCLC):
Approaches on special subgroups and unresolved burning questions.
Cancer Treat Rev. 64:21–29. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Janning M and Loges S: Anti-angiogenics:
Their value in lung cancer therapy. Oncol Res Treat. 41:172–180.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han B, Yang L, Wang X and Yao L: Efficacy
of pemetrexed-based regimens in advanced non-small cell lung cancer
patients with activating epidermal growth factor receptor mutations
after tyrosine kinase inhibitor failure: a systematic review. Onco
Targets Ther. 11:2121–2129. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rho O, Kim DJ, Kiguchi K and Digiovanni J:
Growth factor signaling pathways as targets for prevention of
epithelial carcinogenesis. Mol Carcinog. 50:264–279. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Elsberger B1, Stewart B, Tatarov O and
Edwards J: Is Src a viable target for treating solid tumours? Curr
Cancer Drug Targets. 10:683–694. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gu Z, Fang X, Li C, Chen C, Liang G, Zheng
X and Fan Q: Increased PTPRA expression leads to poor prognosis
through c-Src activation and G1 phase progression in squamous cell
lung cancer. Int J Oncol. 51:489–497. 2017. View Article : Google Scholar : PubMed/NCBI
|
